TLR7 activation by LDV / R848 (Resiquimod) prevents acute graft versus host disease and cooperates with anti-IL-27 antibody for optimal protection

    1. Training
    2. Seminars

    Apr

    12

    TLR7 activation by LDV / R848 (Resiquimod) prevents acute graft versus host disease and cooperates with anti-IL-27 antibody for optimal protection

    From Thursday, April 12, 2018, 5:00 PM to Thursday, April 12, 2018, 9:00 PM

    Lecturer

    Mélanie GAIGNAGE (Promoter: Jean-Paul Coutelier, Co-promoter: Jacques Van Snick)

    Contact

    Mélanie Gaignage
    Gaignage

    Location

    de Visscher Auditorium
    Avenue Hippocrate 74 (Ground Floor)
    1200 Brussels
    Belgium

    Location

    Hall DDUV
    Avenue Hippocrate 75
    1200 Brussels
    Belgium